Distalmotion takes up to $70M loan from Perceptive to push DEXTER into US surgery centers
Swiss surgical robot maker Distalmotion said in a press release on Oct 21 that it has signed a senior secured term loan facility of up to $70 million with Perceptive Advisors to expand sales of its DEXTER system to US ambulatory surgery centers and keep developing the robot and its instruments.
The release gives no interest rate, tranche schedule or amount drawn at signing. The loan follows two $150 million equity rounds in our database, in April 2023 and November 2025.
Distalmotion said in a press release on Oct 21 that it has entered into a senior secured term loan facility of up to $70 million with Perceptive Advisors, a healthcare investment firm. The Lausanne company, which also runs a US office in Cleveland, Ohio, said the money will support further penetration of US ambulatory surgery centers (ASCs) and continued development of the DEXTER Robotic Surgery System and its instrument portfolio.
What the loan pays for, and what the release leaves out
DEXTER is cleared in the US for what Distalmotion calls the four highest-volume soft-tissue outpatient procedures: gallbladder removal, inguinal and ventral hernia repair, and hysterectomy, among others. The company pitches a small, mobile robot with single-use wristed instruments that an ASC can add without rebuilding an operating room or running instruments through sterile processing. Perceptive portfolio manager Sam Chawla said DEXTER is built for the shift of high-volume surgery to ASCs; chief executive Greg Roche said the money will strengthen the US commercial presence. The release does not state the interest rate, the maturity, how much is drawn at signing or what conditions unlock the rest, so "up to $70 million" is a ceiling, not cash in hand.
Debt after two $150 million equity rounds
MEKAWIRE's database lists a $150 million Series F in April 2023, a $150 million Series G led by Revival Healthcare Capital in November 2025 and an undisclosed strategic investment in January 2026 that our earlier story attributed to Johnson & Johnson's venture arm. Disclosed equity since 2023 is therefore $300 million; the new facility at its maximum equals 47% of the Series G.
MEKAWIRE analysis
Choosing a secured loan eleven months after a $150 million equity round is a bet that US surgery-center sales are now predictable enough to service debt, rather than a sign of trouble.
Lenders such as Perceptive price risk on revenue visibility, so the deal says more about DEXTER's US order book than any marketing claim, even though no unit or revenue figures were given. The counter-argument is that debt is cheaper for existing shareholders when a new equity round would come at a lower price, and the release does not let us rule that out. The incumbent sets the scale: Intuitive placed 546 da Vinci systems in the third quarter of 2026 alone. What would change our view: a disclosed DEXTER installed base, a first drawdown figure, or a new equity raise within twelve months.
Latest MEKAWIRE explainer: [Surgical robots market 2026 explained](/news/surgical-robots-market-2026-explained-11710-da-vinci-systems-8400-surgical-robots-sold-challengers-backed-by-medtech-giants-20261017).
- Perceptive Advisors
- Oct 21, 2026, Distalmotion press release
- Senior secured term loan facility, up to $70 million
- Lausanne, Switzerland; US office Cleveland, Ohio
- US ambulatory surgery center expansion; DEXTER and instrument development
- Interest rate, maturity, amount drawn, conditions for later tranches
- Cholecystectomy, inguinal hernia, ventral hernia, hysterectomy, among others
- $150M Series F (Apr 2023), $150M Series G (Nov 2025)